BCL2-Like 1 (BCL2L1) antibody (PE)

Antigen: BCL2-Like 1 (BCL2L1)

Synonyms: BCLX, BCL2L, Bcl-X, bcl-xL, bcl-xS, BCL-XL/S, DKFZp781P2092, BclX, Bcl2l, bcl-x, Bcl-XL, Bcl-Xs, Bcl(X)L, MGC99998, MGC113803, Bclx, bcl-X, Bcl-xl, BCL2L1, Bcl-xL, BCL-XL, bclx, xR11, bcl2l, bclxl, bcl-XL, bcl-xs, MGC69340, bcl-xl/s, bcl-xl, Bcl-xS

Clonality: Monoclonal (7B2-5)

Host: Mouse

Reactivity: Human

Conjugate: PE

Application: Immunoprecipitation (IP), Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (IHC)

Catalog no.: ABIN135024

Additional Information

Alternative name: Bcl-xL

Immunogen: Recombinant Bcl-xS Ig

Isotype: IgG

Clone: 7B2-5

Description: Human Bcl-xL (Mr 29 kDa) Apoptosis, or programmed cell death, is a well-documented phenomenon in many cellular systems.1 It plays a key role in tissue and organ development as well as in adult tissues during cell turnover. Apoptosis can be induced by a variety of internal and external stimuli including growth factor deprivation, cytokine treatment, antigen-receptor engagement, cell-cell interactions, irradiation and glucocorticoid treatment.2 Bcl-2 and one of its homologues, Bcl-xL, protect cells from apoptosis3,4, while other homologues of Bcl-2 such as Bax, Bad and Bak have been shown to enhance apoptosis.5-8 Bcl-xL has been shown to block apoptosis which is induced by a variety of stimuli and, under certain conditions, offers greater protection against apoptosis than Bcl-2.9-13 In contrast, Bad and Bax inhibit the protective functions of Bcl-xL and Bcl-2, respectively. Although heterodimerization between Bcl-xL/Bad and Bcl-2/Bax was originally thought to be essential for the differential anti-apoptotic activity of Bcl-xL and Bcl-2,5,14 other results suggest that the formation of heterodimers may not be necessary for this death-repressing activity.15,16 Mab 7B2.5 recognizes both human and rodent Bcl-xL.

Synonyms: BCLX, BCL2L, Bcl-X, bcl-xL, bcl-xS, BCL-XL/S, DKFZp781P2092, BclX, Bcl2l, bcl-x, Bcl-XL, Bcl-Xs, Bcl(X)L, MGC99998, MGC113803, Bclx, bcl-X, Bcl-xl, BCL2L1, Bcl-xL, BCL-XL, bclx, xR11, bcl2l, bclxl, bcl-XL, bcl-xs, MGC69340, bcl-xl/s, bcl-xl, Bcl-xS

Application Details

Application Notes: Working Dilutions: Flow Cytometry: Purified (3 ug/10^6 cells), Fluorescein (3 ug/10^6 cells), Biotin (3 ug/10^6 cells), R-Phycoerythrin (0.3 ug/10^6 cells), Western Blotting:Purified antibody 0.5 ug/mL Since applications vary, you should determine the optimum working dilution of the product that is appropriate for your specific need.

Storage: The purified (UNLB) antibody is supplied as 0.1 mg of purified immunoglobulin in 1.0 mL of 100 mM borate buffered saline, pH 8.0. No preservatives or amine-containing buffer salts added. Store at 2-8C. The fluorescein (FITC) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN3. Store at 2-8C. The biotin (BIOT) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN3. Store at 2-8C. The R-phycoerythrin (R-PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN3 and a stabilizing agent. Store at 2-8C. Do not freeze! Protect conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed. WARNING Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Research Area: Cancer

Restrictions: For Research Use only

Images

anti-BCL2-Like 1 (BCL2L1) antibody (PE)

Publications

Publications: Cohen: "Programmed cell death in the immune system." in: Advances in immunology, Vol. 50, pp. 55-85, 1991 (PubMed).

Chittenden, Harrington, OConnor et al.: "Induction of apoptosis by the Bcl-2 homologue Bak." in: Nature, Vol. 374, Issue 6524, pp. 733-6, 1995 (PubMed).

Kiefer, Brauer, Powers et al.: "Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak." in: Nature, Vol. 374, Issue 6524, pp. 736-9, 1995 (PubMed).

Yin, Oltvai, Korsmeyer: "BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax." in: Nature, Vol. 369, Issue 6478, pp. 321-3, 1994 (PubMed).

Cheng, Levine, Boise et al.: "Bax-independent inhibition of apoptosis by Bcl-XL." in: Nature, Vol. 379, Issue 6565, pp. 554-6, 1996 (PubMed).

Rajah, Bhala, Nunn et al.: "7S nerve growth factor is an insulin-like growth factor-binding protein protease." in: Endocrinology, Vol. 137, Issue 7, pp. 2676-82, 1996 (PubMed).

Gottschalk, Boise, Oltvai et al.: "The ability of Bcl-x(L) and Bcl-2 to prevent apoptosis can be differentially regulated." in: Cell death and differentiation, Vol. 3, Issue 1, pp. 113-8, 2006 (PubMed).

Urbanska, Lanitis, Poussin et al.: "A universal strategy for adoptive immunotherapy of cancer through use of a novel T cell antigen receptor." in: Cancer research, 2012 (PubMed).